All In Biotech

Drug Trial Radar · NCT06928779

Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant

An Open-Label, Single-Dose, Adaptive Design Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant

Last checked: Nov 19, 2026Latest source record: Apr 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Oct 8, 2024

Primary completion

Dec 9, 2024

Study completion Dec 9, 2024

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will compare the pharmacokinetics (PK) of dazucorilant (CORT113176) between participants with normal hepatic function and participants with hepatic impairment.

Conditions

  • Hepatic Impairment

Interventions

  • DazucorilantDrug

    Dazucorilant 300 mg (4 X 75 mg) soft gelatin capsules for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time curve from time zero to the last non-zero concentration (AUC0-t) of dazucorilantTime frame: Predose and at serial timepoints up to 24 hours after dosing, and at 48, 72, 96, 120, and 144 hours after dosing
  2. Area under the concentration-time curve from time zero to infinity (extrapolated) (AUC0-inf) of dazucorilantTime frame: Predose and at serial timepoints up to 24 hours after dosing, and at 48, 72, 96, 120, and 144 hours after dosing
  3. Maximum observed concentration (Cmax) of dazucorilantTime frame: Predose and at serial timepoints up to 24 hours after dosing, and at 48, 72, 96, 120, and 144 hours after dosing
  4. Time to maximum concentration (Tmax) of dazucorilantTime frame: Predose and at serial timepoints up to 24 hours after dosing, and at 48, 72, 96, 120, and 144 hours after dosing
  5. Apparent clearance (Cl/F) of dazucorilantTime frame: Predose and at serial timepoints up to 24 hours after dosing, and at 48, 72, 96, 120, and 144 hours after dosing

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site 2

    Rialto, California

  • Site 1

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.